Blueprint Medicines to Present Preclinical Data and Provide Enrollment Updates for Phase 1 Clinical Trial for BLU-285 in Advanced Systemic Mastocytosis at ECNM Annual Meeting 2016

CAMBRIDGE, Mass., Oct. 28, 2016 /PRNewswire/ -- Blueprint Medicines Corporation, a leader in discovering and developing highly selective kinase medicines for patients with genomically defined diseases, today announced that preclinical data for Blueprint Medicines' drug candidate BLU-285, a selective inhibitor of Exon 17 mutant KIT and D842V mutant PDGFRα, will be highlighted at the European Competence Network for Mastocytosis (ECNM) Annual Meeting taking place October 27-29, 2016 in Verona, Italy. As part of its presentation, Blueprint Medicines will also provide an update on enrollment in its ongoing Phase 1 clinical trial for BLU-285 in systemic mastocytosis (SM). Blueprint Medicines has submitted an abstract to present preliminary data from the dose escalation portion of this Phase 1 clinical trial at the 2016 American Society of Hematology (ASH) Annual Meeting.  

A copy of the presentation will be available after the presentation and can be accessed under "Events and Presentations" in the Investors section of Blueprint Medicines' website at http://ir.blueprintmedicines.com.

Oral Presentation:

Date & Time: Saturday, October 29, 2016, 9:45-10:00 a.m. CET
Presentation Title: BLU-285, a Potent and Selective Inhibitor for Hematologic Malignancies with KIT Exon 17 Mutations
Presenter: Deepti Radia, MD, Guy and St. Thomas' NHS Foundation Trust
Location: Palazzo della Gran Guardia, Piazza Bra, Verona

About Blueprint Medicines

Blueprint Medicines is developing a new generation of highly selective and potent kinase medicines to improve the lives of patients with genomically defined diseases. The Company's approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Blueprint Medicines is advancing three programs in clinical development for subsets of patients with gastrointestinal stromal tumors, hepatocellular carcinoma and systemic mastocytosis, as well as multiple programs in research and preclinical development. For more information, please visit www.blueprintmedicines.com.

Logo - http://photos.prnewswire.com/prnh/20150605/221118LOGO

SOURCE Blueprint Medicines

Related Links

http://www.blueprintmedicines.com